Digital therapeutics are moving from concept validation to large-scale application, particularly showing immense potential in the field of chronic disease management. According to a randomized controlled trial involving 1,200 patients with type 2 diabetes, recently published in a subsidiary journal of *The Lancet*, after 12 months of digital therapeutic intervention, patients' HbA1c levels decreased by an average of 1.2%, and the target attainment rate improved by 27% compared to the control group. This data marks digital therapeutics as an effective supplementary approach to chronic disease management.
Currently, over 300 digital therapeutic products have received regulatory approval globally, with more than half targeting chronic conditions such as diabetes, hypertension, and obesity. These products provide patients with personalized behavioral interventions, medication reminders, and health data tracking through smartphone applications, wearable devices, and remote monitoring systems.
Background and Significance
Traditional chronic disease management relies on regular outpatient visits and patient self-management, with long-standing issues such as poor adherence and data gaps. The core value of digital therapeutics lies in their "data-driven" and "continuous intervention" capabilities. Taking hypertension management as an example, smart blood pressure monitors and companion applications can record blood pressure fluctuations in real time, with algorithms automatically adjusting dietary recommendations and exercise prescriptions based on the data, while physicians remotely review and adjust treatment plans through backend systems.
Clinical research confirms that this model can significantly reduce the risk of cardiovascular events. The American Heart Association's 2023 scientific statement points out that digital therapeutics are comparable to adding an antihypertensive medication in blood pressure control, with higher patient satisfaction. Additionally, the accessibility and cost-effectiveness of digital therapeutics drive their adoption—compared to traditional outpatient follow-up, digital therapeutics can reduce the cost per management episode by approximately 40%.
Significance for International Patients
For patients seeking medical care across borders, digital therapeutics break down geographical and language barriers. An overseas patient consulting on the MeiCare Health platform can use clinically validated digital therapeutic products at home, with their health data securely synced to the expert end at partner hospitals in Shanghai. Experts can then conduct remote consultations and medication adjustments, eliminating the need for frequent travel.
Taking diabetes management as an example, patients wearing continuous glucose monitors (CGM) generate glucose data every 5 minutes, which, combined with digital therapeutic applications, can predict hypoglycemic events and provide early warnings. This closed-loop management model not only enhances treatment precision but also strengthens patients' self-management capabilities.
How MeiCare Health Helps
MeiCare Health connects global high-quality medical resources, providing international patients with assessment, integration, and follow-up services for digital therapeutics. Our medical services team recommends suitable digital therapeutic products based on patients' disease types, lifestyle habits, and technological familiarity, and assists in connecting with specialist physicians at partner hospitals for remote prescriptions and continuous monitoring.
Additionally, MeiCare Health's cost estimator tool helps patients estimate digital therapeutic-related expenses, including hardware devices, software subscriptions, and remote consultation fees, ensuring cost transparency. If you would like to learn whether digital therapeutics are suitable for your situation, feel free to contact us for personalized advice.
Related reading: Overview of Partner Hospitals in Shanghai